Thus the CCR2-64I variant would be associated with increased risk of cancer in the later stage of tumour development (in this situation after progressing to HSIL) when compared to the CCR2-64V variant which is associated with less stable CCR2A stability and expression. This evidence concerns the gene CCR2 and cancer.